Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01378520 · ClinicalTrials.gov registry record · Phase 4
Effect of Ketoconazole on Breathlessness
A Phase 4 study, sponsored by Dartmouth-Hitchcock Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01378520 is a Phase 4 study that has completed, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 20 participants.
The verdict
NCT01378520, a Phase 4 study, has completed, sponsored by Dartmouth-Hitchcock Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins. The study hypothesis is that oral ketoconazole will reduce ratings of breathlessness induced by resistive breathing loads.
Interventions
- DRUG ketoconazole
- DRUG inert powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-06 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01378520
The ClinicalTrials.gov registry entry for NCT01378520 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ketoconazole is the first listed.
NCT01378520 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01378520 about?
NCT01378520 is a clinical study titled "Effect of Ketoconazole on Breathlessness". Beta-endorphins, which are naturally occurring narcotic substances, have been shown to alter the perception of breathlessness. Oral ketoconazole, an antifungal antibiotic, increases blood levels of beta-endorphins. The study hypothesis is that oral ketoconazole will reduce ratings of breathlessness ...
What is the current status of trial NCT01378520?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-06. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01378520?
The interventions under investigation include: ketoconazole (DRUG), inert powder (DRUG).
Who is sponsoring clinical trial NCT01378520?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.